Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Smith, MR; Saad, F; Chowdhury, S; Oudard, S; Hadaschik, BA; Graff, JN; Olmos, D; Mainwaring, PN; Lee, JY; Uemura, H; Lopez-Gitlitz, A; Trudel, GC; Espina, BM; Shu, Y; Park, YC; Rackoff, WR; Yu, MK; Small, EJ; SPARTAN Investigators.
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
N Engl J Med. 2018; 378(15):1408-1418 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Study Group Mitglieder der Med Uni Graz:
Hutterer Georg C.
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer who were at high risk for the development of metastasis. We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less. Patients were randomly assigned, in a 2:1 ratio, to receive apalutamide (240 mg per day) or placebo. All the patients continued to receive androgen-deprivation therapy. The primary end point was metastasis-free survival, which was defined as the time from randomization to the first detection of distant metastasis on imaging or death. A total of 1207 men underwent randomization (806 to the apalutamide group and 401 to the placebo group). In the planned primary analysis, which was performed after 378 events had occurred, median metastasis-free survival was 40.5 months in the apalutamide group as compared with 16.2 months in the placebo group (hazard ratio for metastasis or death, 0.28; 95% confidence interval [CI], 0.23 to 0.35; P<0.001). Time to symptomatic progression was significantly longer with apalutamide than with placebo (hazard ratio, 0.45; 95% CI, 0.32 to 0.63; P<0.001). The rate of adverse events leading to discontinuation of the trial regimen was 10.6% in the apalutamide group and 7.0% in the placebo group. The following adverse events occurred at a higher rate with apalutamide than with placebo: rash (23.8% vs. 5.5%), hypothyroidism (8.1% vs. 2.0%), and fracture (11.7% vs. 6.5%). Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo. (Funded by Janssen Research and Development; SPARTAN ClinicalTrials.gov number, NCT01946204 .).
Find related publications in this database (using NLM MeSH Indexing)
Adenocarcinoma - drug therapy
Adenocarcinoma - secondary
Aged -
Aged, 80 and over -
Androgen Antagonists - adverse effects
Androgen Antagonists - therapeutic use
Disease Progression -
Disease-Free Survival -
Double-Blind Method -
Exanthema - chemically induced
Humans -
Male -
Middle Aged -
Neoplasm Metastasis - prevention & control
Proportional Hazards Models -
Prostate-Specific Antigen -
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - pathology
Thiohydantoins - adverse effects
Thiohydantoins - therapeutic use

© Meduni Graz Impressum